View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. Comment
January 8, 2019updated 09 Aug 2019 9:33am

Women’s health pipeline: profiling the GCPR target class

Health disorders in women can be caused by many abnormalities in the body and represent a very broad therapy area. Drug development for women’s health disorders has lagged behind other therapy areas, and few new therapies have been approved in the past years.

Health disorders in women can be caused by many abnormalities in the body and represent a very broad therapy area. Drug development for women’s health disorders has lagged behind other therapy areas, and few new therapies have been approved in the past years.

The marketed pharmacotherapeutic treatments for diseases affecting women typically focus on controlling the risk factors and complications in infertility. The G protein-coupled receptor (GPCR) target class makes up 29% of the women’s health pipeline by molecular target.

These include follicle stimulating hormone receptor (FSHR), gonadotrophin-releasing hormone receptor (GnRHR), and oxytocin receptor. The gonadotropin FSH regulates several essential reproductive processes, including gametogenesis, follicular development and ovulation and exerts its effect via activation of the FSHR receptor, a glycoprotein located in the plasma membrane of ovarian granulosa cells.

Developing treatments for women’s health disorders

FSHR mutations and dysregulated FSH-FSHR signalling are associated with infertility and subfertility in women. GNRHR also represents a well-established target within the market.

GnRH is the primary regulator of female reproductive function. By binding to the GnRHR, GnRH induces the synthesis and release of FSH and LH gonadotrophins.

Although the GPCR target class is dominated by targets that are already established in the market, there are a small number of novel targets, including kiss-1 receptor and tachykinin receptor 3, both of which have been recognised as key regulators of reproductive function.

As this is still an emerging class of therapy, this can be expected, and it may take more time for the pipeline size to reflect the commercial dominance. However, despite the relatively small pipeline size, there are opportunities for growth within this group.

For more insight and data, visit the GBI Research report store.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena